China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its rivastigmine twice-weekly transdermal patch (LY03013), a treatment for symptoms of mild and moderate Alzheimer’s disease (AD).
Product Development and Advantages
LY03013, a modified version of rivastigmine, was developed by Luye on its proprietary transdermal patch platform and has already received marketing authorization in several European countries. This twice-weekly patch offers significant advantages over the commercially available rivastigmine single-day transdermal patch, as it reduces administration management demands and improves patient adherence. Compared with oral preparations, Luye’s patch can effectively reduce the incidence of gastrointestinal adverse reactions such as nausea and vomiting through transdermal administration. In the steady state, the blood drug concentration is more stable, providing a more consistent therapeutic effect. Additionally, the product is convenient for patients who have difficulty swallowing oral medications.
Commercialization and Global Partnerships
Changchun GeneScience Pharmaceutical Co., Ltd (GENSCI) entered into a licensing agreement with Luye in December last year, securing the commercialization rights to the product in mainland China. Globally, Luye has established partnerships with local companies in Europe, Japan, and Mexico to expand the reach of the drug.-Fineline Info & Tech
